GRI Bio (GRI) announced the presentation of preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis. The data were ...
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, April 01, 2025 ...
GRI Bio reports positive interim results for GRI-0621 in IPF treatment; patient enrollment nearing completion, cash runway extended to Q3 2025. Cash runway, although extended by a recent public ...
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed ...
Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
The revision came at an unprecedented time. The COVID-19 pandemic highlighted many gaps in understanding the impact of our supply chains on social structures and communities; revealing deep inequities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results